Last month I was still looking into Dynavax. But unfortunately only put it on the watch at first.
The French pharmaceutical group Sanofi is acquiring the US vaccine company Dynavax Technologies Corporation for a value of 2.2 billion US dollars. According to Sanofi, it is offering USD 15.50 per share in cash and the deal is expected to be completed in the first quarter of 2026. With the takeover, Sanofi is securing the HEPLISAV-B drug, a vaccine already marketed in the USA for the prevention of hepatitis B in adults, among other things. The vaccine differs from existing offerings with a two-dose schedule within one month, whereas conventional vaccines require three doses over six months. Dynavax currently has the shingles vaccine candidate Z-1018 in development, which is currently in clinical phase 1/2.
